Prescribing guide
VPRIV (velaglucerase alfa)Dosing, switching from imiglucerase, hypersensitivity management, QuickStart and prior authorization criteria for type 1 Gaucher diseaseFor prescribers and their offices treating gaucher disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. Boxed warning: initiate in a healthcare setting with monitoring and CPR equipment. Start Form, prior authorization (QuickStart may bridge up to 2 doses) and a site of care before the first infusion.
Example PA threshold
Cigna example: age 4 or older; documented deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts, or biallelic pathogenic GBA variants; not for neurological manifestations; specialist prescriber; up to 60 U/kg no more often than every 2 weeks; no concurrent Gaucher therapy.
Monitoring
Supervised infusion with anaphylaxis readiness at every dose; consider premedication after prior hypersensitivity; continue antibody monitoring in patients with an immune response to another ERT; the label sets no laboratory schedule.
Support line
Takeda Patient Support 1-866-888-0660 (Monday to Friday 8:30 am to 8:00 pm ET), Start Form fax 1-888-990-0008; Co-Pay Assistance for eligible commercial plans; QuickStart up to 2 free doses during PA review; PreppedAhead at enrolled sites.
Give your patient their plan
A one-page handout for starting VPRIV, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/vprivBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Submit the Start Form | Complete the VPRIV Start Form through the portal or the downloadable form and fax pages 1 to 3 to 1-888-990-0008. The patient signs the authorization and the Takeda Patient Support enrollment. Phone 1-866-888-0660. | VPRIV Start Form |
| Benefits and PA support | Takeda Patient Support lists benefits investigation; prior authorization, reauthorization and appeals information; and Co-Pay Assistance enrollment for patients who qualify. | VPRIV support programs for HCPs |
| QuickStart | Check the QuickStart box in section 6. Product at no charge for up to 2 doses while a PA is under review; does not cover dosing and administration costs. Not valid for prescriptions covered by Medicaid, Medicare or similar state or federal programs. Patient must be enrolled in Takeda Patient Support. | VPRIV Start Form |
| Site of care | The Start Form takes a site of care or, for home infusion, the home infusion company's address. Takeda Patient Support handles specialty pharmacy or site of care triage and coordination, including during travel or relocation. | VPRIV support programs for HCPs |
| PreppedAhead | Lets the infusion center prepare the dose before the patient arrives. Available only to eligible patients enrolled in Takeda Patient Support whose site of care is enrolled in PreppedAhead; separate sign-up form. | VPRIV support programs for HCPs |
| Calculate vials | 400 unit single-dose vials, individually packaged (NDC 54092-701-04), refrigerated at 2°C to 8°C in the original carton to protect from light; do not freeze. Number of vials from the patient's weight and prescribed dose. | FDA label |
| Reconstitute | 4.3mL Sterile Water for Injection per vial; mix gently, do not shake; yields 100 units/mL (400 units in 4mL). Solution should be clear to slightly opalescent and colorless. | FDA label |
| Dilute | Calculated dose into 100mL of 0.9% sodium chloride; mix gently, do not shake. Slight flocculation is acceptable. Use immediately, or store reconstituted or diluted solution up to 24 hours at 2°C to 8°C, protected from light; complete the infusion within 24 hours of reconstitution. | FDA label |
| Billing code | HCPCS J3385, injection, velaglucerase alfa, 100 units, as listed in the Cigna policy. | Cigna policy |
| Co-Pay Assistance | Commercial only: may cover insurance co-pays for VPRIV at 100% for eligible patients, up to the program maximum; no financial requirements or waiting periods. Subject to a per-claim maximum and an annual calendar year maximum. | VPRIV support programs for HCPs |
| Co-Pay exclusions | Not usable with any federal, state or government-funded program (Medicare, Medicare Advantage, Medicaid, TRICARE), Part D, or insurance paying the entire cost. Takeda may reduce or eliminate assistance under a co-pay maximizer plan. Certain administration charges are not covered where state law prohibits. | VPRIV support programs for HCPs |
Prior authorization criteria and what to document
One public policy as the example: Cigna, June 15, 2026. Approval one year. This policy (Drug Coverage Policy IP0164) took effect June 15, 2026 and cites the September 2024 VPRIV label, the current one. Under a heading for other uses with supportive evidence, it also covers VPRIV for type 3 Gaucher disease on the same terms. That use is outside the FDA label, which covers type 1 only. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis, enzyme route | Deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts [documentation required] | Enzyme assay report | Cigna policy |
| Diagnosis, genetic route | Molecular genetic testing documenting biallelic pathogenic GBA variants [documentation required]; either route qualifies | Genetic test report | Cigna policy |
| Type and age | Type 1 (non-neuronopathic), age 4 years or older. Cigna also covers type 3 on the same criteria under other uses with supportive evidence; type 3 is outside the FDA label, which covers type 1 only | Diagnosis and date of birth in the note | Cigna policy |
| Use | Not for management of neurological manifestations (examples: abnormal ocular movement, auditory impairment, cognitive impairment, seizures) | Treatment goals in the note | Cigna policy |
| Prescriber | Geneticist, endocrinologist, metabolic disorder sub-specialist or lysosomal storage disorder specialist, or in consultation with one | Prescriber specialty or consult note | Cigna policy |
| Dosing | Each dose no more than 60 U/kg IV, no more frequently than once every 2 weeks; other doses reviewed case by case by a clinician | Order with current weight and frequency | Cigna policy |
| Concurrent therapy | Not medically necessary with Cerdelga, Elelyso, Cerezyme or Zavesca | Current medication list | Cigna policy |
| Approval | 1 year; extended approvals allowed if the patient continues to meet the criteria and dosing | Updated criteria at each review | Cigna policy |
VPRIV dosing and titration
| When | Label | Source |
|---|---|---|
| ERT-naive, age 4 and older | 60 units/kg every other week as a 60-minute IV infusion. Adjust on achievement and maintenance of therapeutic goals. | FDA label |
| Switch from imiglucerase | Stable imiglucerase dosage, age 4 and older: start VPRIV at the previous imiglucerase dosage 2 weeks after the last imiglucerase dose. | FDA label |
| Trial doses | Studies I to IV: over 60 minutes at a maximum of 60 units/kg every other week; higher doses not studied. The 45 units/kg arm of Study I is not a recommended starting dose in naive patients. | FDA label |
| Administration set | In-line low protein-binding 0.2 or 0.22 micron filter, over 60 minutes. Do not infuse with other products in the same tubing. | FDA label |
| Before infusion | Consider antihistamines and/or corticosteroids in patients with hypersensitivity symptoms at prior velaglucerase alfa infusions. Patients were not routinely premedicated in clinical studies. | FDA label |
| Hypersensitivity reaction | Manage by severity: slow the rate, treat with antihistamines, antipyretics and/or corticosteroids, and/or stop and resume with increased infusion time. | FDA label |
| Severe reaction | Discontinue VPRIV and immediately initiate appropriate treatment, including epinephrine. | FDA label |
| Pediatric | Established for ages 4 to 17 (74 adult and 20 pediatric patients in the supporting studies); not established under 4 years. | FDA label |
| Missed dose, renal, hepatic | The label gives no missed-dose instruction and no renal or hepatic impairment section. | FDA label |
Monitoring the VPRIV label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion | Hypersensitivity, including anaphylaxis. Most common symptoms in studies: headache, dizziness, hypotension, hypertension, nausea, fatigue/asthenia, pyrexia. Postmarketing: chest discomfort, dyspnea, pruritus, vomiting | Anaphylaxis can occur early or after extended therapy. If severe, discontinue and treat immediately, including epinephrine | FDA label |
| First 6 months | Hypersensitivity reactions: 52% of ERT-naive patients (28 of 54), 23% of patients switched from imiglucerase (9 of 40), including one case of anaphylaxis | Generally mild; in naive patients onset mostly in the first 6 months, less frequent with time | FDA label |
| Antibodies | IgG to VPRIV in 1 of 54 (2%) naive patients plus 1 in an extension study; both neutralizing in vitro; not associated with hypersensitivity reactions | Patients with an immune response to other ERTs who switch should continue to be monitored for antibodies to VPRIV | FDA label |
| After infusion | Post-treatment observation | Takeda's patient site says post-treatment monitoring may be required after the 60-minute infusion; the label sets no observation period | VPRIV infusion page |
| Ongoing | Hemoglobin, platelets, liver and spleen volume were the trial parameters; aPTT prolongation was reported in 11% of naive patients | The label sets no laboratory schedule. Report adverse reactions to Takeda at 1-800-828-2088 | FDA label |
VPRIV drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Contraindications | None | FDA label |
| Drug interactions | The label has no drug interactions section | FDA label |
| Other Gaucher therapies | Concurrent use with Cerdelga, Elelyso, Cerezyme or Zavesca not medically necessary under the Cigna policy; the VPRIV label addresses only the switch from imiglucerase | Cigna policy |
| Pregnancy | More than 300 pregnancies (pharmacovigilance database and published observational cohorts): no association identified with major birth defects, miscarriage or adverse maternal or fetal outcomes; data cannot definitively establish or exclude risk. Pregnancy may exacerbate type 1 disease | FDA label |
| Lactation | No data on presence in human milk; pharmacovigilance cases insufficient to determine effects on the breastfed infant or milk production | FDA label |
| Geriatric | 56 VPRIV-treated patients were 65 or older, including 10 aged 75 or older; adverse reaction profile consistent with other ages; approach dose selection cautiously | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe Cigna policy below asks for a lab report showing low enzyme activity in white blood cells or skin cells, or a genetic test showing changes in both GBA genes.
- The review is taking too longQuickStart may provide up to 2 doses at no charge while a prior authorization is being reviewed. It is not valid for prescriptions covered by Medicaid, Medicare or similar programs.
- The patient is younger than 4Cigna requires age 4 or older. The label says safety and effectiveness have not been established in children younger than 4.
- The doctor is not a specialistCigna asks that VPRIV be prescribed by, or with advice from, a geneticist, endocrinologist, metabolic specialist or lysosomal storage disorder specialist.
- The request mentions brain or nerve symptomsCigna does not cover VPRIV to manage neurological symptoms such as seizures or abnormal eye movement.
- Also taking another Gaucher medicineCigna treats VPRIV used together with Cerdelga, Elelyso, Cerezyme or Zavesca as not medically necessary. Your doctor decides which treatment fits you.
- A dose above the plan's limitCigna allows up to 60 units/kg per dose, no more often than once every 2 weeks. A clinician at the plan reviews other doses case by case.
- A copay you cannot payCommercial insurance: the Takeda Patient Support Co-Pay Assistance Program may cover up to 100% of out-of-pocket copay costs, up to a program maximum. Medicare, Medicare Advantage, Medicaid, TRICARE and other government coverage are excluded.
- Your plan uses a copay maximizerTakeda's terms say it may reduce or end copay help for people whose plan uses a copay maximizer program. The terms ask you to call 1-866-888-0660 if you learn your plan has one.
- Your insurance changesThe copay program's terms say you must tell the program right away, at 1-866-888-0660. Takeda Patient Support also lists help with insurance changes among its services.
Takeda Patient Support
- A support specialist for your questions, with phone help in other languages, including Spanish and Yiddish, through a translation service
- Copay assistance for eligible people with commercial insurance, plus help with reimbursement and insurance issues
- The Co-Pay Assistance Program may cover up to 100% of out-of-pocket copay costs, up to a program maximum, with no financial requirements or waiting periods VPRIV support programs for HCPs
- Copay help cannot be used with Medicare, Medicare Advantage, Medicaid, TRICARE or other government-funded coverage, under the program's terms VPRIV support programs for HCPs
- QuickStart, up to 2 free doses of VPRIV for eligible people while a prior authorization is reviewed
- Coordination between your specialty pharmacy and your site of care, including when you travel or relocate
- PreppedAhead, which lets enrolled sites of care prepare the infusion before you arrive
- Help during life changes such as relocation, moving to college or changing jobs
Questions prescribers' offices ask about VPRIV
What is the VPRIV starting dose for type 1 Gaucher disease?
The November 2024 DailyMed label (prescribing information revised 9/2024) gives 60 units/kg every other week as a 60-minute IV infusion for ERT-naive adults and pediatric patients 4 years and older. Adjust the dosage on achievement and maintenance of each patient's therapeutic goals. Doses above 60 units/kg were not studied.
How is a patient switched from imiglucerase to VPRIV?
Start VPRIV at the previous imiglucerase dosage 2 weeks after the last imiglucerase dose, per section 2.3 of the November 2024 label. This applies to adults and pediatric patients 4 years and older on a stable imiglucerase dosage. In Study III, 40 patients switched at the same number of units and none required a dosage adjustment over 12 months.
Is premedication required before VPRIV infusions?
Section 2.6 of the November 2024 label says to consider antihistamines and/or corticosteroids in patients who had hypersensitivity symptoms with prior velaglucerase alfa infusions. Patients were not routinely premedicated in clinical studies. For a severe reaction, discontinue VPRIV and treat immediately, including epinephrine.
Can VPRIV be infused at home?
The November 2024 label has no home infusion section. It requires initiation in a healthcare setting with monitoring and CPR equipment and sets no number of infusions before a change of site. Every administration should be supervised by a provider knowledgeable in managing hypersensitivity reactions including anaphylaxis. Takeda's patient site says well-tolerated infusions may eventually move home, given by a healthcare professional.
What are the VPRIV prior authorization criteria?
The Cigna policy shown here, IP0164 effective June 15, 2026, approves 1 year for type 1 disease at age 4 or older. Diagnosis needs documented deficient beta-glucocerebrosidase activity or biallelic pathogenic GBA variants. It also requires no use for neurological manifestations, a specialist prescriber, and doses no more than 60 U/kg no more often than every 2 weeks. Concurrent Cerdelga, Elelyso, Cerezyme or Zavesca is not covered.
Free email alert
Get an email when the VPRIV label changes
One email the day the FDA revises the VPRIV prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for VPRIV only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - VPRIV- velaglucerase alfa injection, powder, lyophilized, for solution (updated November 26, 2024, SPL version 27, prescribing information revised 9/2024), Takeda Pharmaceuticals America, Inc., via DailyMed, 2024-11-26.
- VPRIV® Support Programs | VPRIV® (velaglucerase alfa) for injection, Takeda, 2025-05.
- Your VPRIV® Infusion | VPRIV® (velaglucerase alfa) for injection, Takeda, 2025-05.
- VPRIV® (velaglucerase alfa for injection) | Enzyme Replacement Therapy, Takeda, 2026-03.
- Takeda Support Programs | VPRIV® (velaglucerase alfa) for injection, Takeda, 2025-09.
- VPRIV® (velaglucerase alfa) Patient Start Form (US-VEL-0616v1.0 08/24), Takeda, 2024-08.
- Gaucher Disease – Enzyme Replacement Therapy – Vpriv, Drug Coverage Policy IP0164, Cigna, 2026-06-15.
- BLA 022575/S-030 supplement approval letter, enzyme replacement therapy class safety labeling change for hypersensitivity, FDA, 2024-07-10.
- BLA 022575/S-026 supplement approval letter, 0.22 micron filter, immunogenicity and lactation updates, FDA, 2020-12-10.
A reference drawn from the November 26, 2024 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.